It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Osteoarthritis of the Knee or Hip Treatment Study

Clinical Trial Title: 
A phase 3 study evaluating the long-term safety and efficacy of a monoclonal antibody therapy in individuals with osteoarthritis (OA) of the knee or hip compared to oral NSAID therapy.
Clinical Trial Protocol ID: 
12120302
Clinical Trial Investigator Name: 
Joel Block, MD
Clinical Trial Protocol Description: 

The purpose of this study is to determine if subcutaneous injections (injected below the skin) of an investigational drug, are effective in decreasing pain and inflammation for individuals with osteoarthritis of the knee or hip. You will be randomly assigned to one of 3 doses of study drug or placebo. Nationwide, 320 subjects will be recruited for this study. At Rush University Medical Center we expect to recruit approximately 10 subjects.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a diagnosis of osteoarthritis of the hip or knee.
  • Are currently taking one of three oral NSAIDs daily to treat your osteoarthritis pain: naproxen 440-1000mg/day, celecoxib 200mg/day, diclofenac 100-150mg/day, or meloxicam.
  • Have tried other medications, like opioids, to reduce the pain from your osteoarthritis.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a BMI > 39 kg/m2.
  • Have a history of other inflammatory diseases (rheumatoid arthritis, gout or pseudogout, lupus, fibromyalgia, etc.).
  • Are unwilling or unable to undergo an X-ray and MRI.
  • Have had significant trauma or surgery to a knee, hip, or shoulder within the previous year.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Arthritis and Other Rheumatic Diseases
Contact Phone: 
(312) 563-2955
Contact Name: 
Joshlean Fair, MS